

UCSF

UC San Francisco Previously Published Works

Title

The surgical management of diffuse gliomas: Current state of neurosurgical management and future directions.

Permalink

<https://escholarship.org/uc/item/8v40g3zx>

Journal

Neuro-Oncology, 25(12)

Authors

Young, Jacob

Morshed, Ramin

Hervey-Jumper, Shawn

et al.

Publication Date

2023-12-08

DOI

10.1093/neuonc/noad133

Peer reviewed

The surgical management of diffuse gliomas: Current state of neurosurgical management and future directions

Jacob S. Young^o, Ramin A. Morshed^o, Shawn L. Hervey-Jumper, and Mitchel S. Berger

All author affiliations are listed at the end of the article

Corresponding Author: Mitchel S. Berger, MD, Brain Tumor Center, University of California, San Francisco, USA (Mitchel.berger@ucsf.edu).

Abstract

After recent updates to the World Health Organization pathological criteria for diagnosing and grading diffuse gliomas, all major North American and European neuro-oncology societies recommend a maximal safe resection as the initial management of a diffuse glioma. For neurosurgeons to achieve this goal, the surgical plan for both low- and high-grade gliomas should be to perform a supramaximal resection when feasible based on preoperative imaging and the patient's performance status, utilizing every intraoperative adjunct to minimize postoperative neurological deficits. While the surgical approach and technique can vary, every effort must be taken to identify and preserve functional cortical and subcortical regions. In this summary statement on the current state of the field, we describe the tools and technologies that facilitate the safe removal of diffuse gliomas and highlight intraoperative and postoperative management strategies to minimize complications for these patients. Moreover, we discuss how surgical resections can go beyond cytoreduction by facilitating biological discoveries and improving the local delivery of adjuvant chemo- and radiotherapies.

Keywords:

drug delivery | functional brain mapping | glioma | intraoperative tumor identification | maximal safe resection | supratotal resection

A maximal safe surgical resection is recommended as the up-front management for patients with suspected or proven glioblastoma (GBM) or lower-grade diffuse gliomas (LGGs) by all major American and European Oncology societies.^{1,2} Surgical technique and technological advances in the operating room have improved the ability of brain tumor surgeons to safely identify and preserve functional cortical and subcortical regions and locate residual tumor cells. Moreover, postoperative patient management has evolved to improve patient safety and recovery following tumor resection. Given the complexity of these specialized procedures, it is not surprising that high-volume surgeons and centers have been shown to improve outcomes for patients undergoing glioma resections.^{3,4} In this state-of-the-art review, the neurosurgical management of diffuse gliomas is described from initial imaging interpretation of an intra-axial lesion to the intra-operative techniques for maximizing extent

of resection safely. Finally, we will address cutting-edge, surgically implemented adjuvant therapy strategies for the purpose of improving patient outcomes.

Understanding Brain Tumor Classification Criteria in the Molecular Era

Any discussion on the surgical management of diffuse gliomas in adult patients must begin with the recently updated Brain Tumor Diagnosis and Classification schema issued by the World Health Organization in 2021.⁵ This update assigned an even greater emphasis on the molecular characteristics of a tumor when determining a diagnosis, and as a result brain tumor neurosurgeons must be familiar with these molecular

markers to understand patient diagnosis, prognosis, and ultimately management.

The most significant change in the 2021 WHO classification criteria for diffuse gliomas was the elimination of the entity IDH-mutant glioblastoma in adults. In addition, the relevance of homozygous CDKN2A/B deletions on grading for IDH-mutant astrocytomas is now formally recognized—with the presence of a homozygous CDKN2A/B co-deletion resulting in a WHO Grade 4 IDH-mutant diffuse astrocytoma diagnosis. Oligodendrogliomas continue to be classified as either Grade 2 or Grade 3 and must possess both an IDH-mutation and whole-arm deletions of Chromosome 1p and 19q.

Importantly, even with the new WHO classification schema, the tumor grade and/or pathology does not change the upfront surgical plan for diffuse gliomas in adults. Guidelines from all the major American and European oncology and neuro-oncology societies state that the initial management strategy for patients with a lesion concerning for a diffuse glioma is a maximal safe resection.^{1,2} As a result, a biopsy for tissue confirmation prior to definitive surgical resection is not required for lesions consistent with low- or high-grade diffuse glioma on imaging.

The added emphasis on molecular tumor characteristics has placed increased importance on genomic sequencing from tissue specimens to ensure accurate diagnosis.⁶ This practice has reduced inter-rater variability and improved the diagnostic accuracy for diffuse gliomas, particularly when the tissue specimen volume is limited.⁷ Nevertheless, neurosurgeons should be aware of the tissue requirements for the molecular and pathological assays performed, particularly when performing smaller resections or biopsies.

Preoperative Planning

Imaging Interpretation

Paramount to surgical planning is imaging evaluation and interpretation. This involves characterization of a tumor's location—particularly in reference to eloquent cortical and subcortical regions and critical vascular structures. To achieve adequate pre-operative characterization of a lesion, high resolution contrast enhanced T1 weighted sequences, T2/FLAIR sequences, diffusion weighted imaging, susceptibility weighted imaging, and perfusion sequences should routinely be obtained. Certain imaging characteristics, such as T2-FLAIR mismatch, central necrosis, peripheral enhancement, diffuse restriction, and continuity with the cortex can be used to predict if lesions are low- or high-grade and can even be used to predict tumors molecular phenotype.^{8–10} In addition, if an imaging lesion may represent a low grade diffuse glioma but lacks certain characteristics of a neoplasm such as mass effect or expanded cortex and the diagnosis is in question, advanced MR imaging to detect the oncometabolite 2-hydroxyglutarate (2-HG) with spectroscopy can be quite valuable.¹¹ However, as mentioned above, while the grade and molecular traits of the tumor are prognostic and relevant for adjuvant therapy

choices, the surgical goal for all diffuse gliomas is a maximal safe resection, meaning a supramaximal resection of lesional tissue when feasible.

There are several preoperative functional and anatomic imaging studies, including diffusion tensor imaging (DTI) and functional MRI (fMRI) that can be integrated into the overall surgical plan. However, these imaging modalities do not necessarily act as a replacement for intraoperative mapping. While DTI is useful to predict the location of white matter tracts, can aid in surgical planning, and may guide when to begin intraoperative stimulation mapping,¹² DTI alone cannot be used as a replacement for intraoperative electrical stimulation mapping.¹³ In addition, functional MRI (fMRI) can help identify and characterize regions involved in task-specific tasks. Yet, this modality lacks the specificity and anatomic spatial resolution necessary to identify regions critical for language function and is not necessarily a replacement for intraoperative mapping.¹⁴ Accordingly, many brain regions presumed to be eloquent based on preoperative anatomic or functional imaging are actually not eloquent during direct electrical stimulation mapping intraoperatively.¹⁵ As such, “connectomic” maps based on DTI and fMRI are not currently reliable enough to determine eloquence or craft resection plans in the preoperative setting.

Imaging interpretation is more difficult after initial treatment when there is concern for progressive disease. For instance, anatomical MRI sequences are often not sufficient to distinguish true tumor progression from treatment-related changes or pseudoprogression. Physiologic sequences can be used to aid in this distinction for ambiguous lesions, but even still, tissue sampling is often required to confirm the presence and/or quantity of recurrent, viable tumor.¹⁶ O-(2-[¹⁸F] fluoroethyl)-l-tyrosine (FET) or 3,4-dihydroxy-6-¹⁸F-fluoro-l-phenylalanine (F-DOPA) PET scans are valuable imaging adjuncts that have been shown to have a higher accuracy than conventional MRI to distinguish treatment related changes from glioma recurrence.¹⁷ Newer techniques like liquid biopsies are under investigation and may provide additional information about the state of disease, and with the advent of machine learning, radiomic approaches to incorporate artificial intelligence-based decision support into the assessment of MRI lesions have been shown to improve upon the manual assessments of tumor burden (**Figure 1**). These techniques have begun to be incorporated into clinical trial designs and patient care at some institutions.^{18,19}

Preoperative Patient Evaluation

In addition to a standard preoperative evaluation by anesthesia, patients with tumors near language regions should have pre-operative language assessments to determine baseline performance scores and introduce the patient to the tasks that will be used intraoperatively. If there is any question of hemispheric language dominance, preoperative magnetoencephalography, navigated transcranial magnetic stimulation, or fMRI can help localize the side of language function, but similar to DTI, these preoperative functional studies are not suitable to replace intraoperative




Figure 1: Schematic demonstrating techniques for disease monitoring, such as liquid biopsies, radiomics, repeat biopsies, traditional MRI images.

mapping.^{20,21} Behavioral and mental health assessments can be considered when patient's report high levels of distress, depression, or anxiety, all of which are common in patients with diffuse gliomas, impair patient quality of life, and can interfere with intraoperative task performance during awake mapping procedures.²² Moreover, quality of life metrics can be incorporated into the pre- and post-operative patient evaluations and can serve an important role in the discussion of surgical decision-making, particularly for patients with low grade or recurrent lesions. Some surgeons utilize virtual reality and 3D printed models to construct a surgical plan during the preoperative evaluation. Neuropsychological, cognitive, and quality-of-life metrics are becoming more commonplace during the initial work-up of patients with diffuse gliomas, and these measures are useful for understanding the comprehensive impact these diseases have on patients daily functioning over time. Although resource availability and logistical hurdles exist in implementing these multidisciplinary assessments prior to surgery, the incorporation of telehealth into healthcare has created opportunities for patients and providers to perform these evaluations remotely, reducing the burden and some of the challenges associated with obtaining these important preoperative evaluations.²²

For patients with large lesions, significant peritumoral edema, midline shift, or pre-operative language function that is too poor for intraoperative mapping (i.e. baseline error rates > 30%), patients can be admitted to the hospital

for intravenous dexamethasone and mannitol in an effort to reduce the mass effect from peritumoral edema and preoperative language assessments can be repeated to determine if improvements in baseline performance make awake language mapping feasible.²³ If task performance fails to improve sufficiently, the tumor may be resected in a staged approach with the lowest risk language areas removed with asleep motor mapping when appropriate and then a second stage awake approach can be considered to remove the residual lesion depending on the patients performance.²⁴

Surgical Advances for Diffuse Gliomas

Surgical Strategy: The Goal is Supramaximal Safe Resection for All Diffuse Gliomas

Seminal work from the MD Anderson group provided some of the earliest evidence supporting aggressive resections for glioblastoma.²⁵ Although some readers interpreted this paper as supporting an "all-or-nothing" approach with improvements in survival only after EOR surpassed 98% of the contrast-enhancing disease, the data showed increasing survival with increasing degrees of resection above 88% was associated with improved survival regardless of adjuvant treatment. In the era of volumetric tumor

measurements, a stepwise increase in survival was shown as EOR of contrast-enhancing disease increased, and this was true even at the highest levels of EOR, with EOR of 100% of the contrast enhancing disease providing substantial survival benefit above 98% EOR.²⁶ Subsequent studies employing volumetric assessment of tumor size affirmed the benefit of maximal EOR of the contrast enhancing (CE-EOR) disease, and even demonstrated a stepwise increase in overall survival as CE-EOR increased from 90% to 100%.²⁶ The best prospective data supporting aggressive, maximal resections for patients with GBM comes from the randomized control trial investigating fluorescent guided surgery aids like 5-ALA, which definitively showed that patients who received fluorescent dyes had improved EOR and better overall survival.²⁷ Importantly, there is also general agreement amongst brain tumor neurosurgeons regarding which tumors are feasible to resect and which lesions are not amenable for safe resection.²⁸

Recent publications in the molecular era have suggested that supramaximal resections that leave the least amount of residual noncontrast enhancing (nCE) disease provide superior outcomes compared to gross total resection (GTR) of only the CE disease for all diffuse gliomas, regardless of histology, tumor mutational profile, or grade (Figure 2).^{29,30} Li et al. from MD Anderson published in 2016 a study that reported improved overall survival (median survival > 20 months) when more than 50% of the nonenhancing FLAIR abnormality was removed in addition to GTR of the CE component of the tumor.³¹ In a follow-up study from the University of California, San Francisco, in a homogenous cohort of patients that all received standard Stupp protocol adjuvant therapy after surgery, patients younger than 65 years old who had supramaximal resections that left < 5.4 ml of FLAIR abnormality had the best outcomes in the series.³² Other groups have reported similar benefits of supramaximal resections for IDH-WT GBM, although it remains to be determined if resections taken beyond the FLAIR abnormality and into normal appearing tissue on MRI provide an even greater additional relative benefit to

“FLAIRectomies” for GBM.^{33–35} Indeed, a large multicenter, international retrospective series confirmed the value of supramaximal resections that removed greater than 60% of the nCE disease or left a residual nCE volume < 5 cm³.³⁶ However, the benefits of aggressive resections are diminished or abrogated completely if the patient experiences a postoperative neurological deficit, particularly a postoperative motor deficit.^{37,38} This makes the interpretation of FLAIR signal abnormality important, as peritumoral edema, despite containing infiltrating tumor cells, that is not mass-like is not always considered non-enhancing tumor in manuscripts describing supramaximal resections. Moreover, in the high grade setting, where this FLAIR signal more commonly invades white matter tracts, instead of “pushing” or displacing the tracts,³⁹ the interpretation of nonenhancing tumor versus surrounding edema is critical to balance aggressive resection with safety and preservation of function. Importantly, while this is an area of ongoing research and an area where consensus definition is crucial for patient care, maximal resection has not been shown to put patients at risk of postoperative NIHSS or KPS decline in the upfront resection setting.^{40,41}

As the definition of a GTR has historically been based on the contrast-enhancing portion of the tumor for high-grade lesions, consistent terminology for “total” and “supramaximal” resections is critical and recently was defined by Karschnia et al.⁴² For glioblastomas, supramaximal resections are defined as resections beyond the contrast-enhancing margin into tumor regions of FLAIR abnormality. For nonenhancing, low grade gliomas, supramaximal resections are those carried beyond the areas of FLAIR abnormality, and recent evidence suggests this provides additional benefit for LGG compared to traditional GTR.^{43,44} Similar to glioblastoma, studies arguing in favor of aggressive resection for LGG reported survival benefits with GTR of the FLAIR abnormality, as this delayed malignant transformation and improved overall survival.^{45–48} The majority of these reports took place before the molecular era of neuro-oncology, and there have




Figure 2. Illustration showing supramaximal resection definitions for high-grade (a) and low-grade (b) gliomas.

been some retrospective series that state outcomes for patients with 1p/19q co-deleted IDH mutant tumors (i.e. oligodendrogliomas), which are more chemosensitive than astrocytomas, are not as dependent on EOR. However, a recent single-center observation study with long-term follow-up reported lower residual tumor volume after initial resection was a strong prognostic factor in both IDH-mutant astrocytomas and oligodendrogliomas⁴⁹ and a large multicenter retrospective cohort with over 750 patients and 20 years of follow-up found EOR > 75% and minimal residual tumor volumes resulted in the longest overall survival for oligodendroglioma patients.⁴⁴

When low- or high-gliomas recur, the data suggests reoperation should be considered if the patient has good functional status and the tumor recurrence is amenable to re-resection. Although these patients are more heterogeneous with respect to their prior therapy, multiple reports have indicated that reoperation can be performed safely and improve progression free and overall survival for patients with recurrent disease.⁵⁰⁻⁵⁴ The international, multicenter RANO-Resect consortium recently published results from nearly 700 cases of recurrent IDH-WT glioblastoma and found that patients who underwent re-resection and had < 1 cm³ of contrast-enhancing disease had better overall survival than patients who did not undergo re-resection.³⁶ Interestingly, patients who underwent supramaximal re-resections did not have added benefit beyond the maximal re-resection cohort, although supramaximal resections in the recurrent GBM setting were frequently accompanied by new neurological deficits, and the distinction of FLAIR disease from treatment related gliosis is challenging. In the setting of recurrent IDH-mutant LGG, the recently published INDIGO clinical trial results demonstrated that vorasidenib, an oral brain penetrant mutant IDH1/2 inhibitor, could delay time to subsequent intervention and progression free survival for these patients when compared to placebo.⁵⁵ These recent studies highlight the rapidly changing and exciting landscape for patients with recurrent low- and high-grade gliomas, and the decision to re-operate on recurrent disease is nuanced and often benefits from the input of a multi-disciplinary tumor board consisting of neurosurgeons, neuro-oncologists, radiation oncologists, and neuroradiologists.

When to Perform a Biopsy Only and How to Catalog Tissue During Surgery

While maximal safe resection is the standard for lesions amenable to resection, certain patient and tumor characteristics can shift the risk calculus in favor of a biopsy only. Recent work has shown that there is general agreement amongst high-volume tumor surgeons with respect to which lesions should be biopsied only, such as those that cross the midline or extend into more than 3 lobes (previously termed gliomatosis) with no mass effect, or cases where following adjuvant treatment disease recurrence versus pseudoprogression cannot be determined with non-invasive imaging.⁵⁶ Certain patient characteristics, such as very advanced age, extreme frailty, very poor performance status, severe cardiopulmonary comorbidities, and patient preference can also influence the decision to pursue a biopsy rather than resection. Nevertheless, in situations

where a resection is not safe or feasible, it is still important to obtain tissue to confirm the diagnosis, identify targetable genomic mutations, and guide therapeutic decision making.

When obtaining a biopsy, or collecting tissue specimens during tumor resection, brain tumor neurosurgeons should capture the location of the sample on the neuronavigation software, and efforts are underway to facilitate a more standardized approach to catalog the location and characterize of the tissue collected. Careful attention to sample location is especially important for Phase 0 studies where subsequent molecular analyses are needed to determine drug pharmacokinetics/pharmacodynamics. If the institution has the necessary brain tumor research infrastructure, after tissue has been confirmed as pathological on frozen analysis and some tissue has been sent for formalin-fixation and paraffin embedding for diagnostic purposes, any additional tissue should be collected as a fresh specimen for biological analyses and the generation of human PDX tissue culture lines or human tumor organoid models.⁵⁷

Surgical Methods: Stimulation Mapping Techniques

Direct electrical stimulation for the purpose of mapping cortical and subcortical function has repeatedly been shown to minimize post-operative deficits for patients undergoing glioma resection (**Figure 3**). In a large meta-analysis with 8,091 adult patients who underwent resection of glioma, authors found that awake mapping reduced the risk of late, severe neurological deficits from 8.2% to 3.4%.⁵⁸ Additionally, a gross total resection was achieved in 75% of cases with intra-operative stimulation mapping, compared to only 58% of cases without stimulation mapping. Critically, minimizing postoperative deficits not only improves patients quality of life but also preserves the survival benefit of aggressive resections.^{38,59} These results were reinforced by a recent multicenter propensity score-matched analysis study (GLIOMAP), where in the matched cohort of over 500 patients there was a longer PFS and OS with fewer neurological deficits in the awake craniotomy cohort.⁴¹ These findings will be further explored in two upcoming prospective clinical trials: (1) SAFE (NCT03861299), a randomized prospective trial comparing awake craniotomy versus general anesthesia for patients with GBM in eloquent or near eloquent regions and (2) PROGRAM (NCT04708171) a prospective international trial investigating if specific types of intra-operative stimulation mapping (e.g. bipolar, monopolar, transcranial stimulation) yield better results for patients with GBM. While the vast majority of intra-operative mapping tasks aim to preserve motor and language function, evidence exists that executive functions can be identified with stimulation mapping and preservation of these cognitive domains will also be critical for preserving quality of life after glioma surgery.⁶⁰ For certain patients with low grade gliomas whose professional life requires very high-functioning or skilled tasks, additional cognitive mapping tasks can be included in the intra-operative mapping paradigm.




Figure 3. Illustration showing cortical and subcortical monopolar and bipolar mapping techniques.

Positive Versus Negative Mapping Techniques

Historically, a positive mapping site was considered necessary during mapping to ensure that “negative” sites were true negatives; however, negative mapping, where no positive sites are identified, was determined to be as safe as the positive mapping technique in a landmark article.⁶¹ Subsequently, negative mapping has repeatedly been shown to be safe for cortical and subcortical language mapping and is used to facilitate tailored craniotomy windows over the tumor.⁶² While negative mapping allows for smaller craniotomies and exposures, positive mapping remains a viable strategy and the approach should be tailored according to the lesions location and the patient’s symptoms based on the surgeon’s discretion.

Motor Mapping

Motor mapping, which is critical to minimizing postoperative hemiparesis that abrogates the survival benefit for extended restrictions and dramatically impairs patient’s quality of life, has evolved in recent years to include multiple stimulation modalities. Preserving motor function to a degree that maintains a high quality of life requires that patients retain their ability to perform complex motor skills requiring contraction and coordination of multiple muscle groups. Typically, an intraoperative decline in motor evoked potentials (MEPs) more than 50% from the baseline level is indicative of a permanent postoperative deficit.⁶³ Multiple technical advances in motor mapping have facilitated the safe resection of gliomas in or near the Rolandic cortex, and these advances have made both cortical and subcortical motor fiber detection reliable and safe in both the awake and asleep setting.⁶⁴ In the awake setting, transcranial MEPs often require current that generates a painful muscle contraction for the patient, but

direct cortical MEPs are usually well tolerated for patients. The incorporation of monopolar, high-frequency subcortical motor mapping into either awake or asleep mapping strategy has allowed for a quantitative measurement of how close the resection is to the descending CST fibers (every 1 mA increase in amplitude is approximately 1 mm further from the descending CST with traditional train of 5 high frequency stimulation), which is critical to preventing iatrogenic or ischemic injuries to the motor fibers.^{65,66} The electrode and stimulation parameters influence the sensitivity and specificity of both subcortical and monopolar mapping, but in general bipolar motor mapping can produce more selective activation of the corticospinal tract (CST) when the CST is close to the stimulation site whereas monopolar motor mapping is more robust and effective when the CST is far from the stimulation site.⁶⁷ Decreasing the high frequency monopolar subcortical motor mapping monophasic wave pulse to a train of 2 stimulation paradigm rather than the standard train of 5 paradigm can be helpful as the resection approaches the CST as the decreased stimulation train can improve subcortical CST detection specificity.^{68,69} One effective strategy is to utilize the bipolar stimulation to identify the M1 cortex and then rely on frequent monopolar subcortical stimulation during tumor resection to cautiously approach the subcortical motor fibers in combination with frequent MEPs to ensure integrity of the motor pathway.

Testing for apraxia, particularly for tumors in the supplementary motor area (SMA), can be done in addition to cortical and subcortical mapping of the corticospinal tract when the patient is awake,⁷⁰ although this is not necessary to ensure normal long-term neurological function for tumors in the SMA region.⁷¹ For tumors located within the primary motor cortex (M1), Rossi et al. report a high-frequency cortical stimulation approach to identify somatotopic regions within M1 (a fast, more excitable posterior border and a slower anterior border), and while

the architecture of these regions can be distorted by the tumor, if the faster, more excitable component of M1 is preserved, patients strength is much more likely to remain functional.⁷²

Language Mapping

Bipolar Language Mapping

Low-frequency (50–60 Hz) biphasic pulses delivered via a bipolar probe to cortical and subcortical regions in awake patients has been the foundation of language mapping for decades. Various tasks are utilized to identify sites that are critical for the semantic, phonetic, and syntactic components of language function, with picture-naming serving as the work horse for intra-operative language mapping.⁷³ Beyond picture-naming, other tasks such as text reading, picture-word interference, and sentence generation are often employed depending on tumor location and the patient's preoperative language performance.⁷⁴ While this approach is very safe, particularly in high-volume centers, there is some individual variability in the intraoperative electrostimulation parameters required to induce a positive response,⁷⁵ and biphasic stimulation carries a small risk of inducing a seizure. Additionally, bipolar mapping lacks quantitative information regarding the distance to subcortical tracts.⁶²

If patients are struggling to complete the intraoperative tasks, the surgical team can try a few different strategies to obtain a useable intraoperative map. For example, by minimizing the cortical map to the highest risk region that allows for an equatorial approach to the center of the tumor, the mapping portion of the procedure can be expedited and completed in patients who are fatigued, uncomfortable, or anxious. Additionally, limiting the intraoperative testing to words or pictures that patients correctly identified during the preoperative assessment can help ensure intraoperative positive mapping sites are true positives. Finally, using short (e.g. one or two syllable) words can improve the intra-operative performance for patients with moderate to severe pre-operative aphasia.

Monopolar Language Mapping

Traditionally, cortical and subcortical language mapping has been performed with low-frequency, bipolar stimulation. Similar to motor mapping, some groups have explored the use of high-frequency, monopolar, train of five stimulation to map language pathways both cortical and subcortically and found the technique to be safe and effective for mapping anomia and paraphasia.^{76,77} Importantly, cortical monopolar mapping using anodal stimulation while subcortical monopolar stimulation requires cathodal stimulation.⁷⁸ As with the motor system, monopolar stimulation for speech mapping has a much lower risk of inducing a seizure and with similar sensitivity and specificity as bipolar stimulation. Also like motor mapping, some groups have pioneered the use of continuous subcortical monopolar stimulation with suction tips that also serve as a cathodal probe and shown safety with this technique.⁷⁹

Avoiding Postoperative Ischemia

As mapping techniques have improved and facilitated an accurate, quantitative representation of subcortical white matter tracts, confluent areas of ischemia on the early postoperative MRI scan have been shown to be a major cause of new and persistent postoperative neurological deficits.⁸⁰ Importantly, intraoperative relative hypotension has not been shown to be a risk factor for ischemic changes, suggesting tight intraoperative blood pressure regulation to minimize the risk of a hemorrhagic complication is safe.^{80,81} Certain tumor locations, such as the insula, appear to be risk factors for postoperative ischemia and brain tissue adjacent to the tumor may particularly susceptible to transient drops in blood pressure due to a relative regional under-perfusion compared to the tumor itself.⁸² To minimize the risk of postoperative ischemia, meticulous surgical technique to avoid direct or thermal injury to draining veins and perforating arteries is required, and the bipolar electrocautery ideally should be judiciously used during all subcortical tumor resection and must be avoided when within 1 cm of the CST. Additionally, papaverine can be used to avoid vasospasm of delicate lenticulostriate and insular arteries during tumor resection. When an irreversible MEP drop > 50% from baseline is detected intraoperatively, the majority of cases are due to an ischemic lesion that can be identified on the postoperative MRI scan; however, ischemic lesions can also be present and associated with neurological deficits in the absence of intraoperative MEP changes, suggesting the event may occur in a delayed manner.⁶³

Surgical Approaches

Open Craniotomy

An open craniotomy for approaching intra-axial lesions provides a wide cortical exposure, allowing for the selection of a safe cortical entry site following cortical mapping that facilitates a trajectory to the equator of the tumor.⁸³ During these operations, patients are positioned to utilize gravity so that the amount of healthy cortex obscuring the trajectory to the tumor is minimized. Prior to the craniotomy, mannitol and hyperventilation are often used for brain relaxation. If the patient is awake, prior to opening the dura the patient is awakened and asked to take a few deep breaths to exhale carbon dioxide and relax the brain. The patient's body temperature must be kept eutermic during the operation, as hypothermia makes intraoperative mapping less reliable and can reduce patient cooperation. During the resection, the patient's blood pressure is well-controlled to minimize the risk of hemorrhage into the resection bed. Following the craniotomy, the tumor is most commonly approached via a transcortical trajectory to the center or equator of the tumor, ideally along the tumor's long axis to minimize retraction during resection of deep-seated tumors.⁸³ The larger exposure allows for improved visualization of cortical windows and subcortical mapping as the resection progresses. Bimanual dynamic retraction is used to expand the subcortical resection margins within a relatively small cortical window, and fixed retraction should be minimized to avoid injury to the surrounding parenchyma.

Some groups have advocated for a minicraniotomy approach, which is typically described as a linear incision followed by a 3 cm or smaller craniotomy, which have become popular for nonintra-axial lesions such as aneurysms. Some surgeons use an endoscope rather than an operative microscope to improve visualization with these small openings. There have been reports of shorter operative times, shorter hospitalizations, and fewer complications with preserved rates of gross total resection following mini-craniotomy compared to traditional open craniotomies in case series⁸⁴; however, these smaller openings limit the ability to map cortically and subcortically, which as mentioned above, can limit the ability to safely extend resections beyond the contrast-enhancing disease with a minicraniotomy approach. Furthermore, incisions and craniotomies at the time of initial tumor resection should always be made with the mindset that, at the time of tumor recurrence, they will still adequately facilitate tumor exposure. Moreover, the lengths of stay reported in these studies often are 5–7 days on average for both techniques, which is significantly longer than reported lengths of stay reported by some high volume centers following craniotomy for tumor resection.^{81,85}

Keyhole Craniotomy

Even more minimally invasive approaches to intraaxial lesions have been used, termed keyhole or burr hole craniotomies. These very small openings offer limited exposure of the cortical surface for mapping, restricted visualization of deep white matter structures, and a narrow working-space, which may prove risky in the setting of positive cortical/subcortical mapping sites or intraoperative hemorrhage, but proponents of this technique argue that the small working corridor provided is adequate for awake, negative cortical mapping and safe, maximal tumor resections without the need for brain retraction.⁸⁶ Like open craniotomies, surgical experience is critical to become facile and comfortable with these approaches utilizing a narrow working corridor. Reports have shown that these strategies can be used for tumors located in the nondominant and dominant frontal and temporal lobes and with good rates of gross total resection, supramaximal lobectomy, and acceptable complication profiles.^{86,87} Some surgeons have employed the endoscope or tubular retractors in combination with keyhole approaches to improve visualization.⁸⁸ While tubular retractors may be useful for tumors in certain locations (e.g. lesions approximately 2–4 cm from the brain surface where the pathology is easy to differentiate from the normal brain parenchyma),⁸⁹ and these approaches are important components of a brain tumor surgeon's treatment arsenal, there has never been a trial exploring the neurological morbidity and extent of resection between keyhole and traditional open craniotomies, and as the goal of glioma surgery has shifted to more aggressive resections, these techniques may not offer the safest strategy towards achieving this goal.

Ablative Strategies

Ablative techniques are a modification on the keyhole approach, where a minimally invasive burr hole is made but

then the tumor is ablated with hyperthermia via a laser (e.g. LITT) rather than resected with traditional techniques.⁹⁰ Like open resections, LITT ablations should avoid being near functional subcortical pathways or blood vessels. Early reports with this approach have shown a correlation between extent of ablation (EOA) and progression free survival (PFS), with > 70% EOA as the cutoff for benefit.⁹¹ The ablation approach may be most useful for deeper, relatively well-circumscribed lesions that are not contacting the ventricular lining, although the ability to safely pursue supramaximal ablations of large volumes of tumor tissue remains unknown. Laser ablation was explored in a prospective, multi-site registry (LAANTERN, NCT02392078) and reported overall survival outcomes are similar to those of other trials, although the complication rate was slightly higher than that seen for traditional resections in high volume centers, and open surgical resections remain the standard of care as ablative techniques have not been used to achieve supramaximal ablations, do not consider function during the ablation, and there have not been any direct comparisons of EOA against EOR to date.⁹²

Another ablative technique is to use high-frequency focused ultrasound (HiFU) to generate a precise region of thermal ablation. Although this approach is more commonly been used for focal lesions or functional conditions like essential tremor, and there are significant limitations with this approach for large volume tumor ablations or nonfocal disease.⁹³ These ablative strategies are important tools in the surgeon's arsenal and can be considered as long as the surgeon is comfortable that a maximal ablation with minimal morbidity can be achieved.

Determining Resection Margins and Boundaries—Maximizing Safety and Extent of Resection

Successfully identifying the margin between tumor border and normal brain parenchyma is critical to safe maximal resections for gliomas (Figure 4). The integration of new technologies and tumor labeling agents into the operating room has advanced the intra-operative detection of tumor cells and facilitated better, safer tumor resections. Currently, no techniques in practice allow for rapid, intraoperative detection of a tumor's molecular genotype although pseudo-immunohistochemistry and sequencing techniques are rapidly advancing. While the surgical management of diffuse gliomas is not altered by the tumor's molecular status, should targeted therapies become more effective for certain tumors, this rapid assessment of tumor genomics may facilitate tailoring the surgical and treatment strategy in a personalized medicine manner. In the following sections, different intra-operative strategies for identifying residual tumor cells are discussed.

Neuronavigation, DTI, Intraoperative Ultrasound, and Mapping

The use of neuronavigation and DTI in the operating room has been shown to improve EOR and when these




Figure 4. Methods for identification of tumor margins intraoperatively.

technologies are combined with direct electrical stimulation mapping, safety and extent of resection have been shown to be improved than using either technology alone.^{12,47} As resections progress, brain shift decreases the accuracy of navigation systems and tract projections, highlighting the critical need to only stop resections based on function identified with intra-operative mapping, and not on the location of tract fibers generated from pre-operative imaging.⁹⁴ Intraoperative ultrasound, which can now be combined with navigation systems, has the advantage of providing real time information on the location of residual tumor at the resection margin or small satellite lesions around resection cavities, can be used to improve resections when the lesions are subtle or small.⁹⁵ The ultrasound characteristics of the tumor depend on the type of lesion, with the necrotic core of a GBM appearing hypoechoic and low grade lesions appearing slightly hyperechoic to white matter, making this technique versatile and effective for most gliomas; importantly blood and air in the resection cavity can hinder the utility of this tool, particularly for recurrent lesions where gliosis is present.⁹⁶ While

navigated ultrasound can be particularly useful for localizing subcortical lesions at the beginning of resections, the tumor “margin” observed by ultrasound at the end of a resection is often blurred by the iatrogenic manipulation of the tissue during resection and blood products.⁹⁷

Fluorescence Labeling

Agents that can highlight tumor cells under the operative microscope have been explored for decades to improve tumor resections. The two most commonly used fluorescent labels are 5-ALA and fluorescein. Both prospective and retrospective trials, including the Phase 2 multicenter prospective trial FLUOGLIO, have shown that fluorescein is safe and rates of GTR are much higher (around 90%) when fluorescein is used to identify tumor borders intraoperatively.⁹⁸ Importantly, fluorescein stains both contrast-enhancing and nonenhancing tumor regions with a high positive predictive value (PPV > 96%).⁹⁹

5-ALA has been used as an alternative to fluorescein and works in an apparent tumor specific manner,¹⁰⁰ where it gets metabolized by the heme biosynthesis pathway into the fluorescent protoporphyrin IX. Notably, recent single-cell sequencing data suggests that non-neoplastic cells in the tumor micro-environment such as immune cells can also fluoresce, raising some questions about the specificity of these agents for tumor cells.^{100,101} A large randomized Phase 3 trial comparing 5-ALA to standard surgery found higher rates of GTR and increased PFS and OS in the 5-ALA group.²⁷ Similar to fluorescein, the PPV is very high for contrast-enhancing regions, however the negative predictive value is only around 40%, limiting its utility to distinguish the absence of tumor in nonfluorescent tissue.¹⁰² Supporting the concept of supramaximal resections that go beyond the contrast enhancing disease, patients who had residual 5-ALA fluorescence despite complete resection of enhancing tissue on the post-operative MRI had worse overall survival than patients who had no residual fluorescence at the conclusion of the resection.¹⁰³ The specificity and sensitivity of fluorescent labeling adjuncts in the recurrent disease setting has been less well established and there are limitations due to infiltrating inflammatory cells that cause a false positive 5-ALA signal.^{104,105} Nevertheless, fluorescence-guided surgery is a useful adjunct for identifying regions of residual tumor during tumor resection.

Stimulated Raman Histology

Stimulated Raman Histology (SRH) has emerged as a rapid, label-free, nondestructive method that utilizes light to create pseudo-H&E images from fresh tissue specimens. The intraoperative use of SRH has been demonstrated to yield a diagnosis quicker than a traditional frozen specimen (9.7 min vs 43 min) with no difference in the diagnostic accuracy between the two modalities.¹⁰⁶ SRH has also been used to identify residual tumor at the margins of resection cavities, with a high degree of agreement between SRH specimens and traditional H&E specimens when reviewed by pathologists.¹⁰⁷ The speed of Raman histology facilitates the assessment of multiple, serially collected samples to determine if the tumor cell burden is diminished or near-absent at the tumor margin.

Intraoperative MRI

Intraoperative MRI (iMRI) to identify regions of residual tumor before completing the resection and closure has been shown in multiple retrospective and one prospective randomized trial (NCT01394692) to improve extent of resection without increasing surgical morbidity compared to traditional neuronavigation alone.^{108,109} Improved EOR has been reported for both low- and high-grade lesions with iMRI.^{110,111} In practice, iMRI significantly prolongs the surgical procedure and adds complexity for the OR and anesthesia teams.¹¹² Moreover, iMRI has never been shown to result in superior EOR when directly compared to tumor labeling with fluorescent compounds like 5-ALA.¹¹³ More work is needed to determine how iMRI integrates with other rapid intraoperative tumor margin detection methods like 5-ALA and Raman spectroscopy to ultimately establish the role of iMRI in the surgical management of diffuse gliomas.

Intra-Operative and Post-Operative Surgical Adjuncts to Improve Therapeutic Delivery of Agents

Surgically implanted biologically degradable carmustine, or Gliadel® wafers, were one of the first intra-operative drug delivery strategies, and were FDA-approved for newly diagnosed and recurrent glioblastoma after being shown to minimally improve overall survival compared to surgery alone.^{114,115} Recently, there has been a rejuvenated emphasis on interventional means for improving drug delivery or radiation therapy immediately after a tumor resection that incorporate intraoperative adjuncts (Figure 5).

Radiation Implants

Given the majority of GBM recurrences are adjacent to the initial resection cavity where the highest density of residual tumor cells is located, radioactive brachytherapy implants have been used to improve local control rates following tumor resections. Brachytherapy seeds applied at the time of surgery accelerate the time of radiation delivery compared to standard post-operative radiotherapy and may be less costly as this approach can cut down on the number of patient visits associated with adjuvant therapy.¹¹⁶ A variety of radioactive isotopes have been explored, with ¹³¹Cs (a low dose rate of brachytherapy) emerging as a promising agent for CNS tumors given its short half-life compared to ¹²⁵I which translates to lower rates of radiation necrosis.^{117–119} Challenges with brachytherapy include the creation of “hot” and “cold” radiation spots within the tumor due to strand distribution and the threat of radiation necrosis. Currently, there is no data to support intraoperative radiation or brachytherapy for diffuse glioma, with two clinical trials investigating ¹²⁵I failing to show a survival benefit.¹²⁰

The development and FDA-clearance of GammaTile for gliomas and brain metastases, which has ¹³¹Cs titanium encapsulated seeds embedded into a resorbable collagen-based carrier tile, has reinvigorated the interest in brachytherapy and launched the concept of surgically targeted radiation therapy (STaRT).^{121,122} Currently, GammaTile is a 2 cm × 2 cm square tile with four ¹³¹Cs seeds approved for newly diagnosed and recurrent malignant brain tumors capable of delivering 120–150 Gy at the cavity surface and 60–80 Gy at a depth of 5 mm design in a more uniform distribution than traditional brachytherapy seeds.^{123,124} The early clinical reports provide evidence of a reasonable safety profile for GammaTile implants, although there is the potential for delayed seed settling when the collagen scaffold is absorbed and the efficacy remains unknown. The safety and efficacy of GammaTile for CNS tumors is being explored in actively recruiting clinical trials (e.g. ROADS clinical trial)¹²⁵ and early single-arm clinical trial data suggest a reasonable safety profile in recurrent GBM with relatively low rates of radiation adverse effects and modest, short term local control rates.¹²⁶ Importantly, surgeons considering GammaTile should discuss with




Figure 5. Drug delivery strategies/adjuncts that involve neurosurgeons, such as convection-enhanced delivery, radiation implants, low-frequency focused ultrasound.

radiation oncology and neuro-oncology colleagues to ensure that patients remain eligible to enroll in any relevant clinical trials.

Focused Ultrasound

Low-intensity focused ultrasound combined with microbubbles, has emerged as a means of temporarily opening the blood brain barrier for the purpose of improving drug delivery to the tumor without causing tissue damage.⁹³ The low-frequency ultrasound systems currently being explored in clinical trials include an implantable device, called SonoCloud (Carthera, Paris, France),¹²⁷ that does not use image guidance, the ExAblate (InSightec, Haifa, Israel) system, which uses MRI images to guide external, transcranial ultrasound beams to the target, and the NavifUS system which uses neuronavigation and a pretreatment MRI to localize the ultrasound.¹²⁸ Preliminary results for these early-phase clinical trials indicates a substantial increase in drug levels in the peritumoral brain tissue after sonication. Another potentially cytotoxic strategy with focused ultrasound uses this modality in combination with sonosensitizers,

such as 5-ALA, to produce a local cytotoxic effect, termed sonodynamic therapy.¹²⁹

Some groups are also utilizing low frequency FUS mediated BBB disruption to augment the amount of circulating tumor genetic material and tumor antigens, either to enable more accurate liquid biopsies to monitor for tumor progression or treatment response or expose the immune system to more potential targets.^{130,131} The diverse potential of focused ultrasound for neuro-oncology is appealing, and as more studies emerge around this technology neurosurgeons will need to be familiar with the advantages and practical applications of each device.

Convection Enhanced Delivery

Convection enhanced delivery (CED) utilizes stereotactically placed catheters to deliver drugs via bulk flow to the tumor region, allowing for high concentrations of the drug to be achieved in the tumor without systemic toxicity.^{132,133} Better catheter design and improved understanding of catheter positioning has considerably improved CED approaches,¹³⁴ but the inability to deliver repeated treatments has limited this strategy. One solution

to this problem is to embed the therapeutic agents in nanoliposomes to prolong the drugs release after administration (NCT02022644), while a recent publication explores implantable drug pumps as another strategy to facilitate repeated drug dosing with CED.¹³⁵ As technology and the agents delivered via CED continue to improve, neurosurgical oncologists should remain familiar with this drug delivery technique.

Postoperative Care Following Craniotomy for Tumor Resection

The postoperative management of glioma patients is critical to minimizing morbidity. Preventative interventions can be focused on numerous factors including blood pressure control to minimize the risk of a postoperative hematoma, short-term antibiotics for infection prevention, antiepileptics to minimize seizure risk, implementation of steroids to decrease cerebral edema-induced symptoms, and pharmacologic prophylaxis for prevent of deep vein thrombosis. Although randomized control trials are lacking with respect to postoperative patient management, the available evidence can be used to guide effective and safe postsurgical patient care and the establishment of enhanced recovery after surgery (ERAS) pathways following a craniotomy are beginning to introduce standards to the practice.¹³⁶

Blood Pressure Management

Postoperative hypertension has been associated with a risk of intracranial hemorrhage both within the resection cavity and remotely after a craniotomy for tumor resection.^{137,138} A prospective observational study demonstrated that a history of hypertension is the only independent risk factor for postcraniotomy hypertension, and a large percentage of patients require anti-hypertensive treatments transiently after craniotomy for glioma resection.¹³⁹ Despite the risk of post-operative hypertension induced hemorrhage, standardized blood pressure goals after a craniotomy for glioma resection are not well-defined. Within the spontaneous intracerebral hemorrhage patient population, a goal systolic blood pressure < 140 mm Hg has been shown to improve functional outcomes compared to more lenient blood pressure goals, and a target systolic blood pressure < 140 has been described in the literature following elective brain tumor resection as well.^{140,141} Further implementation of even lower systolic blood pressure goals (≤ 120 mm Hg) may be considered following craniotomy for tumor resection since the low intracranial pressure after surgery minimizes the risk of inadequate cerebral perfusion that can be seen with very low systolic pressures.

Corticosteroid Use

Corticosteroids, most commonly dexamethasone, have been used to alleviate vasogenic edema after tumor resections for decades. The initial experience with

dexamethasone typically utilized high-dose regimens like 4 mg dosed every 6 hours to minimize neurological deficits after surgery; however, high-dose and/or prolonged steroid use after resection has been associated with numerous side-effects and even worse survival in patients with glioblastoma.¹⁴² Additionally, given the half-life of dexamethasone is between 36 and 54 hours, prior reports have advocated for less frequent dosing including a twice-daily dosing.¹⁴³ Moreover, if patients are receiving any immune-activating therapies, steroids can reduce the efficacy of the immunotherapy.¹⁴⁴ Indeed, our group has transitioned from a every 6-hr dosing regimen postoperatively to less frequent dosing, often twice daily with a shorter steroid taper if tolerated by the patient.¹⁴⁵

Pharmacologic Deep Vein Thrombosis Prophylaxis

Patients with gliomas are at an increased risk of developing venous thromboembolism (VTE) like deep vein thrombosis (DVT) and pulmonary embolism (PE), with VTE rates as high as 20–30% in some series.¹⁴⁶ While pneumatic compression devices are safe to use and have efficacy in preventing DVTs for craniotomy patients, there are few studies providing guidance on the safety of pharmacological agents for VTE prophylaxis in the postcraniotomy setting.¹⁴⁷ The timing for initiation of DVT prophylaxis has ranged from 1 to 7 days after a craniotomy with some groups preferring to completely avoid pharmacological DVT prophylaxis postoperatively.¹⁴⁸ A study by Smith et al. examined the efficacy of prophylactic with either heparin or enoxaparin and found that earlier initiation on post-operative day 1 was associated with decreased incidence of VTE.¹⁴⁹ In terms of agent selection and dosing, general oncology practice guidelines have recommended low-molecular-weight heparin (LMWH) like enoxaparin for VTE prophylaxis in patients with systemic cancer.¹⁵⁰ However, unfractionated heparin (UH) dosed up to three times a day has been reported to be safe in several studies with glioma patients and a recent meta-analysis suggested there was an increased risk of hemorrhage with low molecular weight heparin (LMWH) compared to UH.^{151,152} More work is needed to define the most appropriate agents to use in the postoperative setting as well as the timing of initiation.

Postoperative Antiepileptics

The use of antiepileptic medications for seizure prevention in patients with brain tumors is somewhat controversial. Consensus statements state that there is no clear benefit for antiepileptics for patients with a brain tumor who do not have a history of seizures.¹⁵³ However, many neurosurgeons give intraoperative anti-epileptic medications and continue them postoperatively to minimize risk of seizures.¹⁵⁴ Yet, randomized trials examining the efficacy of perioperative seizure prophylaxis has failed to show a substantial benefit for seizure prevention.¹⁵⁵

When patients are continued on antiepileptics postoperatively, the duration of treatment varies, often from 1 week to 6 months postoperatively. In a recent study

by Rahman et al. with patients who underwent a craniotomy and did not have prior seizures, the overall rate of seizures was low whether AEDs were continued for 1 or 6 weeks postoperatively.¹⁵⁶ Furthermore, there was no difference in the measurable change in cognition or mood irrespective of duration of therapy. While the agent of choice has not been standardized, many recent studies have investigated levetiracetam given its low side effect profile. In summary, while the current prospective and retrospective literature on antiepileptics for postoperative seizure control have not shown a definitive benefit to seizure control, the side effect profile for newer agents such as levetiracetam is generally favorable with a low risk of cognitive or mood side effects.

Postoperative Imaging

Following tumor resection, an MRI scan typically obtained with 48 hours to evaluate the tumor resection. This early postoperative MRI is valuable as it both shows any residual contrast enhancing or nonenhancing disease, but it also reveals any postoperative ischemic changes on DWI that may enhance on follow up imaging and be mistaken for tumor progression. Furthermore, any ischemic changes are useful for determining the etiology of postoperative neurological deficits when present. Finally, postoperative diffusion tensor imaging may be considered to determine the integrity of white matter tracts around the resection cavity.¹⁵⁷

Rehabilitation

In the event a patient experiences a postoperative neurological deficit, particularly acute paresis, aphasia, or apraxia, a short time period in an acute rehabilitation unit may be necessary for patients to recover to the point that they can return home safely and tolerate adjuvant therapy. During this time, the patient undergoes intensive physical and occupational therapy and equipment necessarily to improve their mobility and quality of life at home can be obtained. In addition to therapy and rehabilitation, there is interest in utilizing technology such as repetitive transcranial magnetic stimulation (rTMS) to enhance plasticity and hopefully improve the speed and magnitude of recovery.¹⁵⁸

Conclusions

In this review statement on the state-of-the-art for neurosurgical oncology, we discuss the prognostic importance of molecular characteristics in the latest diagnostic criteria for diffuse gliomas. Next, although operative approaches may vary, we define the surgical goal for diffuse gliomas and the recent evidence establishing the standard of care for low- and high-grade diffuse gliomas is a focused, open craniotomy for supramaximal resection when safe. The benefit of aggressive resections is limited by postoperative neurological deficits, highlighting the critical importance of safety when

performing these surgeries. We discuss a variety of operative techniques for identifying and preserving functional regions, tracts, and networks intraoperatively and discuss why relying on preoperative data to localize function is not sufficient. We describe emerging technologies for drug delivery, tumor ablation, and adjuvant therapy that have begun to be used for patients with newly diagnosed and recurrent diffuse gliomas, although the data supporting these more novel approaches is somewhat limited. Finally, the postoperative management of patients following a craniotomy for tumor resection is essential for minimizing early post-operative complications; however, there is a general lack of consensus in the field regarding the best patient management practices. Future work is needed to improve standardization across the field of neurosurgical oncology to ensure optimal patient safety and outcomes.

Conflicts of Interest:

The authors have no conflicts of interest to disclose.

Acknowledgements:

The authors would like to acknowledge and thank Ken Probst for providing the illustrations included in this manuscript.

Affiliations

Department of Neurological Surgery, University of California, San Francisco, USA (J.S.Y., R.A.M., S.L.H., M.S.B.)

References

1. Wen PY, Weller M, Lee EQ, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. *Neuro Oncol.* 2020;22(8):1073–1113.
2. Mohile NA, Messersmith H, Gatson NT, et al. Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline. *J Clin Oncol.* 2022;40(4):403–426.
3. Zhu P, Du XL, Zhu, Esquenazi JJ, YlImproved survival of glioblastoma patients treated at academic and high-volume facilities: a hospital-based study from the National Cancer Database. *J Neurosurg.* 2019;132(2):491–502.
4. Raj R, Seppä K, Luostarinen T, et al. Disparities in glioblastoma survival by case volume: a nationwide observational study. *J Neurooncol.* 2020;147(2):361–370.
5. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. *Neuro Oncol.* 2021;23(8):1231–1251.

6. Zhang Y, Lucas C-HG, Young JS, et al. Prospective genomically-guided identification of “early/evolving” and “undersampled” IDH-wildtype glioblastoma leads to improved clinical outcomes. *Neuro Oncol.* 2022;24(10):1749–1762.
7. Iorgulescu JB, Torre M, Harary M, et al. The misclassification of diffuse gliomas: rates and outcomes. *Clin Cancer Res.* 2019;25(8):2656–2663.
8. Kamble AN, Agrawal NK, Koundal S, et al. Imaging-based stratification of adult gliomas prognosticates survival and correlates with the 2021 WHO classification. *Neuroradiology.* 2022;65(1):41–54.
9. Patel SH, Poisson LM, Brat DJ, et al. T2–FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: a TCGA/TCIA project. *Clin Cancer Res.* 2017;23(20):6078–6085.
10. Broen MPG, Smits M, Wijnenga MMJ, et al. The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study. *Neuro Oncol.* 2018;20(10):1393–1399.
11. Choi C, Raisanen JM, Ganji SK, et al. Prospective longitudinal analysis of 2-hydroxyglutarate magnetic resonance spectroscopy identifies broad clinical utility for the management of patients with IDH-mutant glioma. *J Clin Oncol.* 2016;34(33):4030–4039.
12. Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. *Neurosurgery.* 2007;61(5):935–48; discussion 948.
13. Henderson F, Abdullah KG, Verma R, Brem S. Tractography and the connectome in neurosurgical treatment of gliomas: the premise, the progress, and the potential. *Neurosurg Focus.* 2020;48(2):E6.
14. Ellis DG, White ML, Hayasaka S, et al. Accuracy analysis of fMRI and MEG activations determined by intraoperative mapping. *Neurosurg Focus.* 2020;48(2):E13.
15. Chang EF, Clark A, Smith JS, et al. Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. Clinical article. *J Neurosurg.* 2011;114(3):566–573.
16. Young JS, Al-Adli N, Scotford K, Cha S, Berger MS. Pseudoprogression versus true progression in glioblastoma: what neurosurgeons need to know. *J Neurosurg.* 2023;1:1–12.
17. Galldiks N, Niyazi M, Grosu AL, et al. Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. *Neuro Oncol.* 2021;23(6):881–893.
18. Lohmann P, Franceschi E, Vollmuth P, et al. Radiomics in neuro-oncological clinical trials. *Lancet Digit Heal.* 2022;4(11):e841–e849.
19. Vollmuth P, Foltyn M, Huang RY, et al. Artificial intelligence (AI)-based decision support improves reproducibility of tumor response assessment in neuro-oncology: an international multi-reader study. *Neuro Oncol.* 2022;25(3):533–543.
20. Haddad AF, Young JS, Berger MS, Tarapore PE. Preoperative applications of navigated transcranial magnetic stimulation. *Front Neurol.* 2021;11:628903. doi:10.3389/fneur.2020.628903
21. Luna LP, Sherbaf FG, Sair HI, et al. Can preoperative mapping with functional MRI reduce morbidity in brain tumor resection? A systematic review and meta-analysis of 68 observational studies. *Radiology.* 2021;300(2):338–349.
22. Young JS, Al-Adli N, Sibih YE, et al. Recognizing the psychological impact of a glioma diagnosis on mental and behavioral health: a systematic review of what neurosurgeons need to know. *J Neurosurg.* 2022;139(1):1–9.
23. Morshed RA, Young JS, Lee AT, et al. Clinical pearls and methods for intraoperative awake language mapping. *Neurosurgery.* 2021;89(2):143.
24. Hervey-Jumper SL, Li J, Lau D, et al. Awake craniotomy to maximize glioma resection: methods and technical nuances over a 27-year period. *J Neurosurg.* 2015;123(2):325–339.
25. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. *J Neurosurg.* 2001;95(2):190–198.
26. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas: clinical article. *J Neurosurg.* 2011;115(1):3–8.
27. Stummer W, Pichlmeier U, Meinel T, et al; ALA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. *Lancet Oncol.* 2006;7(5):392–401.
28. Müller DMJ, Robe PA, Ardon H, et al. On the cutting edge of glioblastoma surgery: where neurosurgeons agree and disagree on surgical decisions. *J Neurosurg.* 2021;136(1):45–55.
29. Grabowski MM, Recinos PF, Nowacki AS, et al. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma. *J Neurosurg.* 2014;121(5):1115–1123.
30. Kotrotsou A, Elakkad A, Sun J, et al. Multi-center study finds postoperative residual non-enhancing component of glioblastoma as a new determinant of patient outcome. *J Neurooncol.* 2018;139(1):125–133.
31. Li YM, Suki D, Hess K, Sawaya R. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection? *J Neurosurg.* 2016;124(4):977–988.
32. Molinaro AM, Hervey-Jumper S, Morshed RA, et al. Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma. *JAMA Oncol.* 2020;6(4):495–503.
33. Vivas-Buitrago T, Domingo RA, Tripathi S, et al. Influence of supramarginal resection on survival outcomes after gross-total resection of IDH-wild-type glioblastoma. *J Neurosurg.* 2021;136(1):1–8.
34. Haddad AF, Young JS, Morshed RA, Berger MS. FLAIrectomy: resecting beyond the contrast margin for glioblastoma. *Brain Sci.* 2022;12(5):544.
35. Roh TH, Kang SG, Moon JH, et al. Survival benefit of lobectomy over gross-total resection without lobectomy in cases of glioblastoma in the noneloquent area: a retrospective study. *J Neurosurg.* 2019;132(3):895–901.
36. Karschnia P, Young JS, Dono A, et al. Prognostic validation of a new classification system for extent of resection in glioblastoma: a report of the RANO resect group. *Neuro Oncol.* 2022;25(5):940–954.
37. McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma: clinical article. *J Neurosurg.* 2009;110(1):156–162.
38. Aabedi AA, Young JS, Zhang Y, et al. Association of neurological impairment on the relative benefit of maximal extent of resection in chemoradiation-treated newly diagnosed isocitrate dehydrogenase wild-type glioblastoma. *Neurosurgery.* 2022;90(1):124–130.
39. Young JS, Morshed RA, Gogos AJ, et al. The glioma-network interface: a review of the relationship between glioma molecular subtype and intratumoral function. *Neurosurgery.* 2020;87(6):1078–1084.
40. Gerritsen JKW, Zwarthoed RH, Kilgallon JL, et al. Impact of maximal extent of resection on postoperative deficits, patient functioning, and survival within clinically important glioblastoma subgroups. *Neuro Oncol.* 2023;25(5):958–972.
41. Gerritsen JKW, Zwarthoed RH, Kilgallon JL, et al. Effect of awake craniotomy in glioblastoma in eloquent areas (GLIOMAP): a propensity score-matched analysis of an international, multicentre, cohort study. *Lancet Oncol.* 2022;23(6):802–817.
42. Karschnia P, Vogelbaum MA, Van Den Bent M, et al. Evidence-based recommendations on categories for extent of resection in diffuse glioma. *Eur J Cancer.* 2021;149:23–33.
43. Gay L, Rossi M, Conti Nibali M, Sciortino T, Bello L. OS07.7.A Rate and type of recurrence of lower-grade gliomas submitted to functional

- neurosurgical approach: the impact of the extent of resection. *Neuro Oncol.* 2022;24(Supplement_2):ii17–ii17.
44. Hervey-Jumper SL, Zhang Y, Phillips JJ, et al. Interactive effects of molecular, therapeutic, and patient factors on outcome of diffuse low-grade glioma. *J Clin Oncol.* 2023;41(11):2029–2042.
 45. Jakola AS, Myrmet KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. *JAMA - J Am Med Assoc.* 2012;308(18):1881–1888.
 46. McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. *Neurosurgery.* 2008;63(4):700–7; author reply 707.
 47. Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and its impact on overall survival. A single-institution experience in 190 patients: clinical article. *J Neurosurg.* 2012;117(6):1039–1052.
 48. Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. *J Clin Oncol.* 2008;26(8):1338–1345.
 49. van der Vaart T, Wijnga MMJ, van Garderen KA, et al. OS07.8.A Prognosis in IDH-mutant glioma: the role of extent-of-resection, age and tumor grade. *Neuro Oncol.* 2022;24(Supplement_2):ii17–ii17.
 50. Gay L, Rossi M, Sciortino T, et al. P07.08.B Surgical management of recurrent lower-grade gliomas: analysis of oncological and functional outcomes and associated factors. *Neuro Oncol.* 2022;24(Supplement_2):ii41–ii41.
 51. Oppenlander ME, Wolf AB, Snyder LA, et al. An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity. *J Neurosurg.* 2014;120(4):846–853.
 52. Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. *J Neurosurg.* 2012;117(6):1032–1038.
 53. Suchorska B, Weller M, Tabatabai G, et al. Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma—results from the DIRECTOR trial. *Neuro Oncol.* 2016;18(4):549–556.
 54. Wann A, Tully PA, Barnes EH, et al. Outcomes after second surgery for recurrent glioblastoma: a retrospective case-control study. *J Neurooncol.* 2018;137(2):409–415.
 55. Mellinshoff IK, van den Bent MJ, Blumenthal DT, et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. *N Engl J Med.* 2023. doi: [10.1056/NEJMoa2304194](https://doi.org/10.1056/NEJMoa2304194). Epub ahead of print. PMID: 37272516.
 56. Kommers IO, Eijgelaar RS, Barkhof F, et al. P11.37.B When to resect or biopsy for patients with supratentorial glioblastoma: a multivariable prediction model. *Neuro Oncol.* 2022;24(Supplement_2):ii65–ii66.
 57. Darrigues E, Elberson BW, De Loose A, et al. Brain tumor biobank development for precision medicine: role of the neurosurgeon. *Front Oncol.* 2021;11:662260.
 58. De Witt Hamer PC, Robles SG, Zwinderman AH, Duffau H, Berger MS. Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. *J Clin Oncol.* 2012;30(20):2559–2565.
 59. McGirt MJ, Mukherjee D, Chaichana KL, et al. Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. *Neurosurgery.* 2009;65(3):463–470.
 60. Puglisi G, Sciortino T, Rossi M, et al. Preserving executive functions in nondominant frontal lobe glioma surgery: an intraoperative tool. *J Neurosurg.* 2018;131(2):474–480.
 61. Sanai N, Mirzadeh Z, Berger MS. Functional outcome after language mapping for glioma resection. *N Engl J Med.* 2008;358(1):18–27.
 62. Gogos AJ, Young JS, Morshed RA, Hervey-Jumper SL, Berger MS. Awake glioma surgery: technical evolution and nuances. *J Neurooncol.* 2020;147(3):515–524.
 63. Gempt J, Krieg SM, Hüttinger S, et al. Postoperative ischemic changes after glioma resection identified by diffusion-weighted magnetic resonance imaging and their association with intraoperative motor evoked potentials. *J Neurosurg.* 2013;119(4):829–836.
 64. Gogos AJ, Young JS, Morshed RA, et al. Triple motor mapping: transcranial, bipolar, and monopolar mapping for supratentorial glioma resection adjacent to motor pathways. *J Neurosurg.* 2020;134(6):1728–1737.
 65. Schucht P, Seidel K, Jilch A, Beck J, Raabe A. A review of monopolar motor mapping and a comprehensive guide to continuous dynamic motor mapping for resection of motor eloquent brain tumors. *Neurochirurgie.* 2017;63(3):175–180.
 66. Rossi M, Sani S, Nibali MC, et al. Mapping in low-grade glioma surgery: low- and high-frequency stimulation. *Neurosurg Clin N Am.* 2019;30(1):55–63.
 67. Gomez-Tames J, Kutsuna T, Tamura M, Muragaki Y, Hirata A. Intraoperative direct subcortical stimulation: comparison of monopolar and bipolar stimulation. *Phys Med Biol.* 2018;63(22):225013.
 68. Rossi M, Conti Nibali M, Viganò L, et al. Resection of tumors within the primary motor cortex using high-frequency stimulation: oncological and functional efficiency of this versatile approach based on clinical conditions. *J Neurosurg JNS.* 2020;133(3):642–654.
 69. Rossi M, Sciortino T, Conti Nibali M, et al. Clinical pearls and methods for intraoperative motor mapping. *Neurosurgery.* 2021;88(3):457–467.
 70. Fornia L, Puglisi G, Leonetti A, et al. Direct electrical stimulation of the premotor cortex shuts down awareness of voluntary actions. *Nat Commun.* 2020;11(1):1–11.
 71. Young JS, Gogos AJ, Aabedi AA, et al. Resection of supplementary motor area gliomas: revisiting supplementary motor syndrome and the role of the frontal aslant tract. *J Neurosurg.* 2021;136(5):1278–1284.
 72. Rossi M, Viganò L, Puglisi G, et al. Targeting Primary Motor Cortex (M1) functional components in M1 gliomas enhances safe resection and reveals M1 plasticity potentials. *Cancers.* 2021;13(15):3808.
 73. Chang EF, Raygor KP, Berger MS. Contemporary model of language organization: an overview for neurosurgeons. *J Neurosurg.* 2015;122(2):250–261.
 74. Young JS, Lee AT, Chang EF. A review of cortical and subcortical stimulation mapping for language. *Neurosurgery.* 2021;89(3):331–342.
 75. Roux FE, Durand JB, Djidjeli I, Moyse E, Giussani C. Variability of intraoperative electrostimulation parameters in conscious individuals: language cortex. *J Neurosurg.* 2017;126(5):1641–1652.
 76. Riva M, Fava E, Gallucci M, et al. Monopolar high-frequency language mapping: can it help in the surgical management of gliomas? A comparative clinical study. *J Neurosurg.* 2016;124(5):1479–1489.
 77. Verst SM, de Aguiar PHP, Joaquim MAS, et al. Monopolar 250–500 Hz language mapping: results of 41 patients. *Clin Neurophysiol Pract.* 2019;4:1–8.
 78. Seidel K, Beck J, Stieglitz L, Schucht P, Raabe A. The warning-sign hierarchy between quantitative subcortical motor mapping and continuous motor evoked potential monitoring during resection of supratentorial brain tumors; Clinical article. *J Neurosurg.* 2013;118(2):287–296.
 79. Axelson HW, Latini F, Jemstedt M, Ryttefors M, Zetterling M. Continuous subcortical language mapping in awake glioma surgery. *Front Oncol.* 2022;12:4137.
 80. van der Boog ATJ, Rados M, Akkermans A, et al. Occurrence, risk factors, and consequences of postoperative ischemia after glioma resection: a retrospective study. *Neurosurgery.* 1990;92(1):125–136.
 81. Morshed RA, Young JS, Gogos AJ, et al. Reducing complication rates for repeat craniotomies in glioma patients: a single-surgeon experience and comparison with the literature. *Acta Neurochir.* 2022;164(2):405–417.

82. Waqar M, Lewis D, Agushi E, et al. Cerebral and tumoral blood flow in adult gliomas: a systematic review of results from magnetic resonance imaging. *Br J Radiol.* 2021;94(1125):20201450.
83. Morshed RA, Young JS, Han SJ, Hervey-Jumper SL, Berger MS. The transcortical equatorial approach for gliomas of the mesial temporal lobe: techniques and functional outcomes. *J Neurosurg.* 2019;130(3):822–830.
84. Paolini S, Severino R, Mancarella C, et al. Mini-craniotomy for intra-axial brain tumors: a comparison with conventional craniotomy in 306 patients harboring non-dural based lesions. *Neurosurg Rev.* 2022;45(4):2983–2991.
85. Young JS, Chan AK, Viner JA, et al. A Safe Transitions Pathway for post-craniotomy neurological surgery patients: high-value care that bypasses the intensive care unit. *J Neurosurg.* 2020;134(5):1386–1391.
86. Burks JD, Conner AK, Bonney PA, et al. Frontal keyhole craniotomy for resection of low- and high-grade gliomas. *Neurosurgery.* 2018;82(3):388–396.
87. Conner AK, Burks JD, Baker CM, et al. Method for temporal keyhole lobectomies in resection of low- and high-grade gliomas. *J Neurosurg.* 2017;128(5):1388–1395.
88. Ansari SF, Eisenberg A, Rodriguez A, Barkhoudarian G, Kelly DF. The supraorbital eyebrow craniotomy for intra- and extra-axial brain tumors: a single-center series and technique modification. *Oper Neurosurg.* 2020;19(6):667–677.
89. Eichberg DG, Di L, Shah AH, et al. Minimally invasive resection of intracranial lesions using tubular retractors: a large, multi-surgeon, multi-institutional series. *J Neurooncol.* 2020;149(1):35–44.
90. Schupper AJ, Chanenchuk T, Racanelli A, Price G, Hadjipanayis CG. Laser hyperthermia: past, present, and future. *Neuro Oncol.* 2022;24(Suppl 6):S42–S51.
91. Di L, Wang CP, Shah AH, et al. A cohort study on prognostic factors for laser interstitial thermal therapy success in newly diagnosed glioblastoma. *Neurosurgery.* 2021;89(3):496–503.
92. de Groot JF, Kim AH, Prabhu S, et al. Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma. *Neuro-Oncology Adv.* 2022;4(1):vdac040.
93. Bunevicius A, McDannold NJ, Golby AJ. Focused ultrasound strategies for brain tumor therapy. *Oper Neurosurg.* 2020;19(1):9–18.
94. Nimsky C, Ganslandt O, Hastreiter P, et al. Intraoperative diffusion-tensor MR imaging: shifting of white matter tracts during neurosurgical procedures—initial experience. *Radiology.* 2005;234(1):218–225.
95. Moiraghi A, Prada F, Delaidelli A, et al. Navigated intraoperative 2-dimensional ultrasound in high-grade glioma surgery: impact on extent of resection and patient outcome. *Oper Neurosurg.* 2020;18(4):363–373.
96. Dixon L, Lim A, Grech-Sollars M, Nandi D, Camp S. Intraoperative ultrasound in brain tumor surgery: a review and implementation guide. *Neurosurg Rev.* 2022;45(4):2503–2515.
97. Yeole U, Singh V, Mishra A, et al. Navigated intraoperative ultrasonography for brain tumors: a pictorial essay on the technique, its utility, and its benefits in neuro-oncology. *Ultrasonography.* 2020;39(4):394–406.
98. Acerbi F, Broggi M, Schebesch KM, et al. Fluorescein-guided surgery for resection of high-grade gliomas: a multicentric prospective phase II study (FLUOGLIO). *Clin Cancer Res.* 2018;24(1):52–61.
99. Neira JA, Ung TH, Sims JS, et al. Aggressive resection at the infiltrative margins of glioblastoma facilitated by intraoperative fluorescein guidance. *J Neurosurg.* 2017;127(1):111–122.
100. McCracken DJ, Schupper AJ, Lakomkin N, et al. Turning on the light for brain tumor surgery: a 5-aminolevulinic acid story. *Neuro Oncol.* 2022;24(Suppl 6):S52–S61.
101. Liu Z, Mela A, Furnari J, et al. Single-cell analysis of 5-ALA intraoperative labeling specificity for glioblastoma. *bioRxiv.* 2022:2022.12.17.520870.
102. Lau D, Hervey-Jumper SL, Chang S, et al. A prospective Phase II clinical trial of 5-aminolevulinic acid to assess the correlation of intraoperative fluorescence intensity and degree of histologic cellularity during resection of high-grade gliomas. *J Neurosurg.* 2016;124(5):1300–1309.
103. Aldave G, Tejada S, Pay E, et al. Prognostic value of residual fluorescent tissue in glioblastoma patients after gross total resection in 5-aminolevulinic acid-guided surgery. *Neurosurgery.* 2013;72(6):915–20; discussion 920.
104. Chohan MO, Berger MS. 5-Aminolevulinic acid fluorescence guided surgery for recurrent high-grade gliomas. *J Neurooncol.* 2019;141(3):517–522.
105. Ricciardi L, Sturiale CL, Scerrati A, et al. 5-aminolevulinic acid false-positive rates in newly diagnosed and recurrent glioblastoma: do pseudoprogression and radionecrosis play a role? A meta-analysis. *Front Oncol.* 2022;12:848036.
106. Di L, Eichberg DG, Huang K, et al. Stimulated Raman histology for rapid intraoperative diagnosis of gliomas. *World Neurosurg.* 2021;150:e135–e143.
107. Pekmezci M, Morshed RA, Chunduru P, et al. Detection of glioma infiltration at the tumor margin using quantitative stimulated Raman scattering histology. *Sci Rep.* 2021;11(1):12162.
108. Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. *Lancet Oncol.* 2011;12(11):997–1003.
109. Kubben PL, ter Meulen KJ, Schijns OEMG, et al. Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review. *Lancet Oncol.* 2011;12(11):1062–1070.
110. Shah AS, Sylvester PT, Yahanda AT, et al. Intraoperative MRI for newly diagnosed supratentorial glioblastoma: a multicenter-registry comparative study to conventional surgery. *J Neurosurg.* 2020;135(2):1–10.
111. Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. *Cancer.* 2005;103(6):1227–1233.
112. Pichierri A, Bradley M, Iyer V. Intraoperative magnetic resonance imaging-guided glioma resections in awake or asleep settings and feasibility in the context of a public health system. *World Neurosurg X.* 2019;3:100022.
113. Golub D, Hyde J, Dogra S, et al. Intraoperative MRI versus 5-ALA in high-grade glioma resection: a network meta-analysis. *J Neurosurg.* 2020;134(2):484–498.
114. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. *Lancet (London, England).* 1995;345(8956):1008–1012.
115. Kotecha R, Odia Y, Khosla AA, Ahluwalia MS. Key clinical principles in the management of glioblastoma. *JCO Oncol Pract.* 2023;19(4):180–189.
116. Barbarite E, Sick JT, Berchmans E, et al. The role of brachytherapy in the treatment of glioblastoma multiforme. *Neurosurg Rev.* 2017. 40(2):195–211. doi: [10.1007/s10143-016-0727-6](https://doi.org/10.1007/s10143-016-0727-6).
117. Chen WC, Lafreniere M, Phuong C, et al. Resection with intraoperative cesium-131 brachytherapy as salvage therapy for recurrent brain tumors. *J Neurosurg.* 2022;137(4):924–930.
118. Han DY, Ma L, Braunstein S, et al. Resection cavity contraction effects in the use of radioactive sources (1-25 versus Cs-131) for intraoperative brain implants. *Cureus.* 2018;10(1):e2079.
119. Gutin PH, Leiber SA, Wara WM, et al. Recurrent malignant gliomas: survival following interstitial brachytherapy with high-activity iodine-125 sources. *J Neurosurg.* 1987;67(6):864–873.
120. Laperriere NJ, Leung PMK, McKenzie S, et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. *Int J Radiat Oncol Biol Phys.* 1998;41(5):1005–1011.

121. Gessler DJ, Ferreira C, Dusenbery K, Chen CC. GammaTile: surgically targeted radiation therapy for glioblastomas. *Futur Oncol.* 2020;16(30):2445–2455.
122. Odia Y, Gutierrez AN, Kotecha R. Stereotactic targeted radiation therapy (STaRT) trials for brain neoplasms: a comprehensive review. *Neuro Oncol.* 2022;24(Suppl 6):S16–S24.
123. Youssef E, Nakaji P, Thomas T, et al. SCDT-36. Novel modular, permanently implanted collagen-based device for intraoperative brachytherapy in patients with central nervous system tumors. *Neuro Oncol.* 2017;19(suppl_6):vi272–vi272.
124. Brachman D, Youssef E, Dardis C, et al. Surgically targeted radiation therapy: safety profile of collagen tile brachytherapy in 79 recurrent, previously irradiated intracranial neoplasms on a prospective clinical trial. *Brachytherapy.* 2019;18(3):S35–S36.
125. Gessler DJ, Neil EC, Shah R, et al. GammaTile brachytherapy in the treatment of recurrent glioblastomas. *Neuro-oncology Adv.* 2021;4(1):vdab185.
126. Smith K, Nakaji P, Thomas T, et al. Safety and patterns of survivorship in recurrent GBM following resection and surgically targeted radiation therapy: results from a prospective trial. *Neuro Oncol.* 2022;24(Suppl 6):S4–S15.
127. Idbaih A, Sonabend A, Stupp R, et al. OS07.3.A Phase 1/2 clinical trial of blood-brain barrier opening with the SonoCloud-9 implantable ultrasound device in recurrent glioblastoma patients receiving IV carboplatin. *Neuro Oncol.* 2022;24(Supplement_2):ii16–ii16.
128. Roberts JW, Powlovich L, Sheybani N, LeBlang S. Focused ultrasound for the treatment of glioblastoma. *J Neurooncol.* 2022;157(2):237–247.
129. Raspagliesi L, D'Ammando A, Gionso M, et al. Intracranial sonodynamic therapy with 5-aminolevulinic acid and sodium fluorescein: safety study in a porcine model. *Front Oncol.* 2021;11:679989.
130. Zhu L, Cheng G, Ye D, et al. Focused ultrasound-enabled brain tumor liquid biopsy. *Sci Rep.* 2018;8(1):1–9.
131. Soffietti R, Bettgowda C, Mellinghoff IK, et al. Liquid biopsy in gliomas: a RANO review and proposals for clinical applications. *Neuro Oncol.* 2022;24(6):855–871.
132. Vogelbaum MA, Iannotti CA. Convection-enhanced delivery of therapeutic agents into the brain. *Handb Clin Neurol/ Ed by PJ Vinken GW Bruyn.* 2012;104:355–362.
133. Jahangiri A, Chin AT, Flanigan PM, et al. Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies. *J Neurosurg.* 2016;126(1):191–200.
134. Sampson JH, Archer G, Pedain C, et al; PRECISE Trial Investigators. Poor drug distribution as a possible explanation for the results of the PRECISE trial. *J Neurosurg.* 2010;113(2):301–309.
135. Spinazzi EF, Argenziano MG, Upadhyayula PS, et al. Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial. *Lancet Oncol.* 2022;23(11):1409–1418.
136. Elayat A, Jena SS, Nayak S, Sahu RN, Tripathy S. Enhanced recovery after surgery - ERAS in elective craniotomies-a non-randomized controlled trial. *BMC Neurol.* 2021;21(1):127.
137. Basali A, Mascha EJ, Kalfas L, Schubert A. Relation between perioperative hypertension and intracranial hemorrhage after craniotomy. *Anesthesiology.* 2000;93(1):48–54.
138. Seifman MA, Lewis PM, Rosenfeld JV, Hwang PYK. Postoperative intracranial haemorrhage: a review. *Neurosurg Rev.* 2011;34(4):393–407.
139. Perez CA, Stutzman S, Jansen T, et al. Elevated blood pressure after craniotomy: a prospective observational study. *J Crit Care.* 2020;60:235–240.
140. Hanak BW, Walcott BP, Nahed BV, et al. Postoperative intensive care unit requirements after elective craniotomy. *World Neurosurg.* 2014;81(1):165–172.
141. Anderson CS, Heeley E, Huang Y, et al; INTERACT2 Investigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. *N Engl J Med.* 2013;368(25):2355–2365.
142. Pitter KL, Tamagno I, Alikhanyan K, et al. Corticosteroids compromise survival in glioblastoma. *Brain.* 2016;139(Pt 5):1458–1471.
143. Lim-Fat MJ, Bi WL, Lo J, et al. Letter: when less is more: dexamethasone dosing for brain tumors. *Neurosurgery.* 2019;85(3):E607–E608.
144. Koch MS, Zdioruk M, Nowicki MO, et al. Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models. *J Immunother Cancer.* 2022;10(1):e003368.
145. Breshears JD, Haddad AF, Viner J, et al. A reduced exogenous steroid taper for postoperative brain tumor patients-a case-control study. *World Neurosurg.* 2019;125:e44–e47.
146. Simanek R, Vormittag R, Hassler M, et al. Venous thromboembolism and survival in patients with high-grade glioma. *Neuro Oncol.* 2007;9(2):89–95.
147. Auguste KI, Quiñones-Hinojosa A, Berger MS. Efficacy of mechanical prophylaxis for venous thromboembolism in patients with brain tumors. *Neurosurg Focus.* 2004;17(4):E3.
148. Briggs RG, Lin YH, Dadario NB, et al. Optimal timing of postoperative enoxaparin after neurosurgery: a single institution experience. *Clin Neurol Neurosurg.* 2021;207:106792. doi: [10.1016/j.clineuro.2021.106792](https://doi.org/10.1016/j.clineuro.2021.106792)
149. Smith TR, Lall RR, Graham RB, et al. Venous thromboembolism in high grade glioma among surgical patients: results from a single center over a 10 year period. *J Neurooncol.* 2014;120(2):347–352.
150. O'Connell C, Escalante CP, Goldhaber SZ, et al. Treatment of cancer-associated venous thromboembolism with low-molecular-weight heparin or direct oral anticoagulants: patient selection, controversies, and caveats. *Oncologist.* 2021;26(1):e8–e16.
151. Thirunavu V, Kandula V, Shah P, et al. Unfractionated heparin TID dosing regimen is associated with a lower rate of pulmonary embolism when compared with BID dosing in patients undergoing craniotomy. *World Neurosurg.* 2021;153:e147–e152. doi: [10.1016/j.wneu.2021.106792](https://doi.org/10.1016/j.wneu.2021.106792)
152. Bell JS, Florence TJ, Phillips HW, et al. Comparison of the safety of prophylactic anticoagulants after intracranial surgery. *Neurosurgery.* 2021;89(3):527–536.
153. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology.* 2000;54(10):1886–1893.
154. Siomin V, Angelov L, Li L, Vogelbaum MA. Results of a survey of neurosurgical practice patterns regarding the prophylactic use of anti-epilepsy drugs in patients with brain tumors. *J Neurooncol.* 2005;74(2):211–215.
155. Wu AS, Trinh VT, Suki D, et al. A prospective randomized trial of perioperative seizure prophylaxis in patients with intraparenchymal brain tumors. *J Neurosurg.* 2013;118(4):873–883.
156. Rahman M, Eisenschenk S, Melnick K, et al. Duration of prophylactic levetiracetam after surgery for brain tumor: a prospective randomized trial. *Neurosurgery.* 2022;92(1):68–74.
157. Caverzasi E, Hervey-Jumper SL, Jordan KM, et al. Identifying preoperative language tracts and predicting postoperative functional recovery using HARDI q-ball fiber tractography in patients with gliomas. *J Neurosurg.* 2016;125(1):33–45.
158. Ille S, Kelm A, Schroeder A, et al. Navigated repetitive transcranial magnetic stimulation improves the outcome of postsurgical paresis in glioma patients: a randomized, double-blinded trial. 2021;14(4):780–787. doi: [10.1016/j.brs.2021.04.026](https://doi.org/10.1016/j.brs.2021.04.026).